Matthew G Fury

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Current recommendations for systemic therapy of recurrent and/or metastatic head and neck squamous cell cancer
    Matthew G Fury
    Head and Neck Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Natl Compr Canc Netw 9:681-9. 2011
  2. doi request reprint A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer
    Matthew G Fury
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer 118:5008-14. 2012
  3. doi request reprint A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC)
    Matthew G Fury
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 532, New York, NY 10021, USA
    Cancer Chemother Pharmacol 70:121-8. 2012
  4. doi request reprint A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors
    Matthew G Fury
    Department of Medicine, Head and Neck Medical Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 532, New York, NY, 10021, USA
    Cancer Chemother Pharmacol 69:591-8. 2012
  5. ncbi request reprint Tissue microarray evidence of association between p16 and phosphorylated eIF4E in tonsillar squamous cell carcinoma
    Matthew G Fury
    Head and Neck Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Head Neck 33:1340-5. 2011
  6. doi request reprint A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer
    Matthew G Fury
    Head and Neck Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 117:795-801. 2011
  7. pmc A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer
    Matthew G Fury
    Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA
    Cancer 119:1823-31. 2013
  8. doi request reprint A phase 1 study of everolimus + weekly cisplatin + intensity modulated radiation therapy in head-and-neck cancer
    Matthew G Fury
    Department of Medicine, Head and Neck Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York Department of Medicine, Weill Cornell Medical College, New York, New York
    Int J Radiat Oncol Biol Phys 87:479-86. 2013
  9. pmc Tumor metabolism and perfusion in head and neck squamous cell carcinoma: pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F]FDG-PET
    Jacobus F A Jansen
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Int J Radiat Oncol Biol Phys 82:299-307. 2012
  10. pmc Dynamic contrast-enhanced magnetic resonance imaging as a predictor of outcome in head-and-neck squamous cell carcinoma patients with nodal metastases
    Amita Shukla-Dave
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Radiat Oncol Biol Phys 82:1837-44. 2012

Detail Information

Publications29

  1. ncbi request reprint Current recommendations for systemic therapy of recurrent and/or metastatic head and neck squamous cell cancer
    Matthew G Fury
    Head and Neck Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Natl Compr Canc Netw 9:681-9. 2011
    ..Avenues for ongoing research are also presented...
  2. doi request reprint A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer
    Matthew G Fury
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer 118:5008-14. 2012
    ..HNSCC tumors that express high levels of vascular endothelial growth factor have been associated with a worse prognosis, and bevacizumab may sensitize tumors to cisplatin and radiation...
  3. doi request reprint A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC)
    Matthew G Fury
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 532, New York, NY 10021, USA
    Cancer Chemother Pharmacol 70:121-8. 2012
    ..The mammalian target of rapamycin complex 1 (mTORC1) is aberrantly activated in many head and neck squamous cell carcinomas (HNSCCs). This phase I study combines the mTORC1 inhibitor temsirolimus with carboplatin and paclitaxel...
  4. doi request reprint A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors
    Matthew G Fury
    Department of Medicine, Head and Neck Medical Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 532, New York, NY, 10021, USA
    Cancer Chemother Pharmacol 69:591-8. 2012
    ..We conducted a phase I study to establish the recommended phase II of oral everolimus to be given with low-dose weekly intravenous cisplatin...
  5. ncbi request reprint Tissue microarray evidence of association between p16 and phosphorylated eIF4E in tonsillar squamous cell carcinoma
    Matthew G Fury
    Head and Neck Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Head Neck 33:1340-5. 2011
    ..The purpose of this study is to determine if p16 immunoreactivity is associated with aberrant expression of components of the PI3 kinase pathway...
  6. doi request reprint A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer
    Matthew G Fury
    Head and Neck Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 117:795-801. 2011
    ..A phase 1 study of pemetrexed plus gemcitabine given every 2 weeks demonstrated encouraging preliminary efficacy against head and neck squamous cell cancer (HNSCC)...
  7. pmc A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer
    Matthew G Fury
    Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA
    Cancer 119:1823-31. 2013
    ..The authors conducted a phase 1 study to evaluate the addition of oral everolimus to cisplatin and docetaxel as induction chemotherapy for head and neck cancer...
  8. doi request reprint A phase 1 study of everolimus + weekly cisplatin + intensity modulated radiation therapy in head-and-neck cancer
    Matthew G Fury
    Department of Medicine, Head and Neck Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York Department of Medicine, Weill Cornell Medical College, New York, New York
    Int J Radiat Oncol Biol Phys 87:479-86. 2013
    ..Preclinically, inhibition of mTORC1 with everolimus sensitizes cancer cells to cisplatin and radiation...
  9. pmc Tumor metabolism and perfusion in head and neck squamous cell carcinoma: pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F]FDG-PET
    Jacobus F A Jansen
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Int J Radiat Oncol Biol Phys 82:299-307. 2012
    ..Additionally, pretreatment multimodality imaging was evaluated for its efficacy in predicting short-term response to treatment...
  10. pmc Dynamic contrast-enhanced magnetic resonance imaging as a predictor of outcome in head-and-neck squamous cell carcinoma patients with nodal metastases
    Amita Shukla-Dave
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Radiat Oncol Biol Phys 82:1837-44. 2012
    ..The goal of this study was to assess the prognostic value of pretreatment DCE-MRI in head and neck squamous cell carcinoma (HNSCC) patients with nodal disease undergoing chemoradiation therapy or surgery...
  11. doi request reprint Intensity-modulated radiation therapy in oropharyngeal carcinoma: effect of tumor volume on clinical outcomes
    Benjamin H Lok
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Radiat Oncol Biol Phys 82:1851-7. 2012
    ..To analyze the effect of primary gross tumor volume (pGTV) and nodal gross tumor volume (nGTV) on treatment outcomes in patients treated with definitive intensity-modulated radiation therapy (IMRT) for oropharyngeal cancer (OPC)...
  12. doi request reprint Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab
    Matthew D Hellmann
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical School, 300 East 66th Street, New York, NY 10065, USA
    Cancer Chemother Pharmacol 72:453-61. 2013
    ..The risk of hemoptysis may be eliminated in patients with resected SQCLCs. We evaluated the safety of adjuvant bevacizumab in patients with resected SQCLCs and other lung cancers at high risk of hemoptysis...
  13. pmc Evaluation of romidepsin for clinical activity and radioactive iodine reuptake in radioactive iodine-refractory thyroid carcinoma
    Eric J Sherman
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Thyroid 23:593-9. 2013
    ..In thyroid cancer cell lines, romidepsin increases expression of both thyroglobulin and the sodium iodide symporter messenger RNAs, suggesting the possibility of improved iodine concentrating ability of RAI-resistant tumors...
  14. pmc Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)
    Matthew G Fury
    Head and Neck Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Anticancer Res 31:249-53. 2011
    ..Saracatinib (AZD0530) is an orally available Src kinase inhibitor. A phase II study was conducted to evaluate saracatinib in patients with recurrent or metastatic head and neck squamous cell cancer (HNSCC)...
  15. doi request reprint Target volume delineation in oropharyngeal cancer: impact of PET, MRI, and physical examination
    Anuradha Thiagarajan
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Radiat Oncol Biol Phys 83:220-7. 2012
    ..This study aims to evaluate contributions of magnetic resonance imaging (MRI), positron emission tomography (PET), and physical examination (PE) to GTV delineation in oropharyngeal cancer (OPC)...
  16. pmc Impact of obesity on the survival of patients with early-stage squamous cell carcinoma of the oral tongue
    Neil M Iyengar
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
    Cancer 120:983-91. 2014
    ..Although obesity increases risk and negatively affects survival for many malignancies, the prognostic implications in squamous cell carcinoma (SCC) of the oral tongue, a disease often associated with prediagnosis weight loss, are unknown...
  17. ncbi request reprint Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers
    Jamie E Chaft
    Department of Medicine, Division of Solid Tumor Oncology, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York 10065, USA
    J Thorac Oncol 8:1084-90. 2013
    ..Bevacizumab improves survival in patients with advanced non-small-cell lung cancer (NSCLC). This phase II clinical trial assessed the effects of the addition of bevacizumab to neoadjuvant chemotherapy in resectable nonsquamous NSCLC...
  18. ncbi request reprint A phase II study of pralatrexate with vitamin B12 and folic acid supplementation for previously treated recurrent and/or metastatic head and neck squamous cell cancer
    Alan L Ho
    Department of Medicine, Memorial Sloan Kettering Cancer Center MSKCC, 300 E 66th Street, New York, NY, 10065, USA
    Invest New Drugs 32:549-54. 2014
    ..We conducted a phase II study of pralatrexate with folic acid and B12 supplementation in patients with recurrent and/or metastatic head and neck squamous cell cancer (R/M HNSCC)...
  19. doi request reprint Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: an update of the Memorial Sloan-Kettering Cancer Center experience
    Jeremy Setton
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Int J Radiat Oncol Biol Phys 82:291-8. 2012
    ..To update the Memorial Sloan-Kettering Cancer Center's experience with intensity-modulated radiotherapy (IMRT) in the treatment of oropharyngeal cancer (OPC)...
  20. ncbi request reprint A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer
    Matthew G Fury
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Natl Compr Canc Netw 10:1391-8. 2012
    ..Cetuximab, 500 mg/m(2), q2w achieves similar efficacy as conventional dosing for patients with recurrent or metastatic HNSCC. Escalating the dose to 750 mg/m(2) q2w offers no obvious therapeutic advantage...
  21. doi request reprint Molecular-targeted therapies in head and neck cancer
    Shyam D Rao
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Semin Radiat Oncol 22:207-13. 2012
    ..In this article, we review strategies aimed at key pathways, including EGF receptor signaling, the Vascular Endothelial Growth Factor (VEGF) pathway, and PI3K/AKT/mammalian target of rapamycin activation...
  22. pmc Noninvasive assessment of tumor microenvironment using dynamic contrast-enhanced magnetic resonance imaging and 18F-fluoromisonidazole positron emission tomography imaging in neck nodal metastases
    Jacobus F A Jansen
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Int J Radiat Oncol Biol Phys 77:1403-10. 2010
    ....
  23. ncbi request reprint A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors
    Matthew G Fury
    Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10021, USA
    Cancer Chemother Pharmacol 57:671-7. 2006
    ..The aim of this phase I study was to determine the maximum-tolerated dose of pralatrexate when combined with probenecid given every 2 weeks in humans...
  24. ncbi request reprint A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors
    Matthew G Fury
    Division of Solid Tumor Oncology, Head and Neck Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Immunol Immunother 57:155-63. 2008
    ..Preclinical data suggest that co-administration of granulocyte-colony stimulating factor (G-CSF) may enhance the tumor cytotoxicity of bispecific antibodies...
  25. ncbi request reprint A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors
    Matthew G Fury
    Division of Solid Tumor Oncology, Head and Neck Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10021, USA
    Cancer Chemother Pharmacol 59:467-75. 2007
    ....
  26. doi request reprint Induction chemotherapy in the management of head and neck cancer
    Matthew G Fury
    Head and Neck Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Surg Oncol 101:292-8. 2010
    ....
  27. doi request reprint Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: a critical re-evaluation including uniform pathologic review
    Eric J Sherman
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, United States
    Radiother Oncol 101:425-30. 2011
    ..We evaluated our more recent experience with this approach, which included pathologic confirmation of all cases...
  28. ncbi request reprint A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers
    Matthew G Fury
    Head and Neck Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Invest New Drugs 25:165-72. 2007
    ..This Phase II study was conducted to determine the safety and efficacy of SU5416 in patients with recurrent or metastatic head and neck cancers...
  29. ncbi request reprint A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy
    Matthew G Fury
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021 6007, USA
    Cancer J 11:241-7. 2005
    ..Characteristics at presentation and prognostic factors are reviewed. For patients with unresectable disease, progression-free survival with various chemotherapy regimens is described...